RECOVERY

Phase 3

Recruiting

Conditions: Pneumonia

Registration Number: 2023-507441-29-00

Lead Sponsor: University Of Oxford

Brief Summary: To provide reliable estimates of the effect of study treatments on mortality and time to discharge from hospital

Detailed Description: Not available

Recruitment & Eligibility

Status: Ongoing, recruiting

Sex: Not specified

Target Recruitment: 1790

Inclusion Criteria

Hospitalised patients aged ≥18 years

Pneumonia syndrome (clinical diagnosis, in general based on a) typical symptoms of new respiratory infection, b) objective evidence of acute lung disease [e.g. hypoxia or compatible imaging or clinical examination], and c) alternative causes considered unlikely

One of the following diagnoses: a) Confirmed influenza A or B infection b) Community-acquired pneumonia with planned antibiotic treatment (without suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis, or Pneumocystis pneumonia)

No medical history that might, in the opinion of the patient’s doctor, put the patient at significant risk if he/she were to participate in the trial

No reason that the trial treatment definitely should, or should not, be given in the opinion of the patient’s doctor (this only affects eligibility for the relevant comparison)

Exclusion Criteria

No exclusion criteria

Study & Design

Study Type: Not specified

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
28 day all-cause mortality		28 day all-cause mortality
Time to discharge alive from hospital within 28 days (patients with influenza only)		Time to discharge alive from hospital within 28 days (patients with influenza only)

Secondary Outcome Measures

Name	Time	Method
Time to discharge alive from hospital within 28 days (patients without influenza)		Time to discharge alive from hospital within 28 days (patients without influenza)
Progression to invasive mechanical ventilation (including extracorporeal membrane oxygenation) or death within 28 days		Progression to invasive mechanical ventilation (including extracorporeal membrane oxygenation) or death within 28 days

Trial Locations

Locations (66): Amsterdam UMC
🇳🇱
Amsterdam, Netherlands
Jeroen Bosch Ziekenhuis
🇳🇱
's-Hertogenbosch, Netherlands
Amphia Hospital
🇳🇱
Breda, Netherlands
Universitair Ziekenhuis Gent
🇧🇪
Gent, Belgium
Jessa Ziekenhuis
🇧🇪
Hasselt, Belgium
Cliniques Universitaires Saint-Luc
🇧🇪
Sint-Lambrechts-Woluwe, Belgium
UZ Leuven
🇧🇪
Leuven, Belgium
CHU Saint-Pierre
🇧🇪
Bruxelles, Belgium
Tartu University Hospital
🇪🇪
Tartu Linn, Estonia
Sihtasutus Parnu Haigla
🇪🇪
Parnu Linn, Estonia
Scroll for more (56 remaining)
Amsterdam UMC
🇳🇱Amsterdam, Netherlands
Joost Wiersinga
Site contact
+31641375729
w.j.wiersinga@amsterdamumc.nl